OB1
0.002
100%
PYC
0.85
-30%
LRD
0.042
82.6%
ORP
0.03
-25%
RCM
0.053
55.9%
VAR
0.006
-25%
JAV
0.003
50%
G88
0.008
-20%
MMR
0.006
50%
NGX
0.16
-20%
CYQ
0.007
40%
WBE
0.004
-20%
CCE
0.105
38.2%
OKJ
0.037
-17.8%
IS3
0.011
37.5%
LML
0.005
-16.7%
SFM
0.295
37.2%
CXU
0.011
-15.4%
AA2
0.39
34.5%
KTA
0.011
-15.4%
AQC
0.008
33.3%
M4M
0.006
-14.3%
COY
0.016
33.3%
NWM
0.012
-14.3%
CZN
0.004
33.3%
ICR
0.025
-13.8%
MOH
0.008
33.3%
KLR
0.29
-13.4%
CNQ
0.34
30.8%
BMN
3.27
-12.8%
AQX
0.005
25%
ANX
0.007
-12.5%
CNJ
0.005
25%
SW1
0.007
-12.5%
RLG
0.005
25%
VKA
0.007
-12.5%
DBO
0.036
24.1%
TMB
0.043
-12.2%
RIM
0.016
23.1%
EMV
2.05
-11.6%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Cleo Diagnostics (ASX:COV): Bringing to market a simple blood test

Cleo Diagnostics (ASX:COV) is attempting to bring to market a simple blood test for the accurate and early diagnosis of ovarian cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in nonmalignant disease. The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide | Investor presentation: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02774453-3A636747